FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912782246> ?p ?o ?g. }

• W2912782246 endingPage "S336" @default.
• W2912782246 startingPage "S336" @default.
• W2912782246 abstract "The temporal cell surface expression of lymphocyte activated gene 3 (LAG3) on recently activated T cells presents an opportunity for targeted therapy in certain inflammatory diseases. LAG3+ cells are enriched in inflamed lesions in ulcerative colitis,1 Crohn’s disease and psoriasis. GSK2831781 is a highly potent, humanised IgG1, antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody that depletes LAG3+ cells. A single escalating intravenous dose of GSK2831781 or placebo was administered to 40 healthy volunteers (up to 0.15 mg/kg). Three cohorts of nine patients with mild–moderate psoriasis were randomised to GSK2831781 (0.5, 1.5, or 5 mg/kg) or placebo in a 2:1 ratio. Safety, tolerability, pharmacokinetics (PK), and immunogenicity were evaluated. Circulating LAG3+ T cells were quantified using flow cytometry. LAG3+ and CD3+ cell counts and transcriptomics were assessed in psoriatic skin biopsies acquired prior to dosing and at Day 29. Psoriasis activity severity indices (PASI) and plaque lesion severity scores (PLSS) were profiled. GSK2831781 was well-tolerated with no safety concerns identified. PK was non-linear, partly explained by target-mediated drug disposition; the non-linear process was saturated at doses ≥0.5 mg/kg. Dose-dependent depletion of circulating LAG3+ memory T cells was observed for 6–8 weeks following a single 5 mg/kg dose. LAG3+ and CD3+ (Figure 1) cells were reduced in psoriasis skin biopsies at 1.5 and 5 mg/kg. Preliminary analysis showed down-regulation of pro-inflammatory mRNA transcripts (IL-17F, IFN-γ, and S100A12) and up-regulation of those associated with epithelial integrity (CDHR1) which met the threshold of ≥1.5-fold change in median values vs. placebo at 5 mg/kg. There was no apparent decrease to Treg-associated transcripts (IL-10 and FOXP3). GSK2831781 improved PASI and PLSS (Figure 1) at all doses (difference of estimated mean change from baseline in PLSS vs. placebo for 5 mg/kg, on Day 29 was −2.01 [95% CI: −3.57, −0.44]). The per cent change from baseline PLSS mean for 5 mg/kg, Day 29 was −30.9% (SD: 13.41) vs. placebo −1.9% (SD: 22.40). Figure 1 GSK2831781 effected dose-dependent depletion of LAG3+ T cells in blood, reduced LAG3+ and CD3+ cells in psoriatic skin and exhibited encouraging effects on pro-inflammatory and epithelial integrity transcripts, which translated into clinical improvements. These data are supportive of Phase II studies in other T-cell-related diseases, including inflammatory bowel disease. Reference 1. Slevin S, Tan M, Lahiff C, et al. Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis. J Crohn’s Colitis 2018;S125. doi:10.1093/ecco-jcc/jjx180.191" @default.
• W2912782246 created "2019-02-21" @default.
• W2912782246 creator A5006002179 @default.
• W2912782246 creator A5008339860 @default.
• W2912782246 creator A5014494732 @default.
• W2912782246 creator A5016183651 @default.
• W2912782246 creator A5022620838 @default.
• W2912782246 creator A5031033749 @default.
• W2912782246 creator A5033902641 @default.
• W2912782246 creator A5036281891 @default.
• W2912782246 creator A5037371315 @default.
• W2912782246 creator A5042471205 @default.
• W2912782246 creator A5047417215 @default.
• W2912782246 creator A5048060049 @default.
• W2912782246 creator A5059057844 @default.
• W2912782246 creator A5059860640 @default.
• W2912782246 creator A5066687267 @default.
• W2912782246 creator A5066798507 @default.
• W2912782246 creator A5068012825 @default.
• W2912782246 creator A5075930262 @default.
• W2912782246 creator A5083531787 @default.
• W2912782246 creator A5090039049 @default.
• W2912782246 creator A5090850829 @default.
• W2912782246 date "2019-01-25" @default.
• W2912782246 modified "2023-10-16" @default.
• W2912782246 title "P449 Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial" @default.
• W2912782246 doi "https://doi.org/10.1093/ecco-jcc/jjy222.573" @default.
• W2912782246 hasPublicationYear "2019" @default.
• W2912782246 type Work @default.
• W2912782246 sameAs 2912782246 @default.
• W2912782246 citedByCount "3" @default.
• W2912782246 countsByYear W29127822462020 @default.
• W2912782246 countsByYear W29127822462023 @default.
• W2912782246 crossrefType "journal-article" @default.
• W2912782246 hasAuthorship W2912782246A5006002179 @default.
• W2912782246 hasAuthorship W2912782246A5008339860 @default.
• W2912782246 hasAuthorship W2912782246A5014494732 @default.
• W2912782246 hasAuthorship W2912782246A5016183651 @default.
• W2912782246 hasAuthorship W2912782246A5022620838 @default.
• W2912782246 hasAuthorship W2912782246A5031033749 @default.
• W2912782246 hasAuthorship W2912782246A5033902641 @default.
• W2912782246 hasAuthorship W2912782246A5036281891 @default.
• W2912782246 hasAuthorship W2912782246A5037371315 @default.
• W2912782246 hasAuthorship W2912782246A5042471205 @default.
• W2912782246 hasAuthorship W2912782246A5047417215 @default.
• W2912782246 hasAuthorship W2912782246A5048060049 @default.
• W2912782246 hasAuthorship W2912782246A5059057844 @default.
• W2912782246 hasAuthorship W2912782246A5059860640 @default.
• W2912782246 hasAuthorship W2912782246A5066687267 @default.
• W2912782246 hasAuthorship W2912782246A5066798507 @default.
• W2912782246 hasAuthorship W2912782246A5068012825 @default.
• W2912782246 hasAuthorship W2912782246A5075930262 @default.
• W2912782246 hasAuthorship W2912782246A5083531787 @default.
• W2912782246 hasAuthorship W2912782246A5090039049 @default.
• W2912782246 hasAuthorship W2912782246A5090850829 @default.
• W2912782246 hasBestOaLocation W29127822461 @default.
• W2912782246 hasConcept C126322002 @default.
• W2912782246 hasConcept C142724271 @default.
• W2912782246 hasConcept C197934379 @default.
• W2912782246 hasConcept C203014093 @default.
• W2912782246 hasConcept C204787440 @default.
• W2912782246 hasConcept C27081682 @default.
• W2912782246 hasConcept C2776090121 @default.
• W2912782246 hasConcept C2777011040 @default.
• W2912782246 hasConcept C2778375690 @default.
• W2912782246 hasConcept C2780564577 @default.
• W2912782246 hasConcept C71924100 @default.
• W2912782246 hasConcept C8891405 @default.
• W2912782246 hasConcept C98274493 @default.
• W2912782246 hasConceptScore W2912782246C126322002 @default.
• W2912782246 hasConceptScore W2912782246C142724271 @default.
• W2912782246 hasConceptScore W2912782246C197934379 @default.
• W2912782246 hasConceptScore W2912782246C203014093 @default.
• W2912782246 hasConceptScore W2912782246C204787440 @default.
• W2912782246 hasConceptScore W2912782246C27081682 @default.
• W2912782246 hasConceptScore W2912782246C2776090121 @default.
• W2912782246 hasConceptScore W2912782246C2777011040 @default.
• W2912782246 hasConceptScore W2912782246C2778375690 @default.
• W2912782246 hasConceptScore W2912782246C2780564577 @default.
• W2912782246 hasConceptScore W2912782246C71924100 @default.
• W2912782246 hasConceptScore W2912782246C8891405 @default.
• W2912782246 hasConceptScore W2912782246C98274493 @default.
• W2912782246 hasIssue "Supplement_1" @default.
• W2912782246 hasLocation W29127822461 @default.
• W2912782246 hasOpenAccess W2912782246 @default.
• W2912782246 hasPrimaryLocation W29127822461 @default.
• W2912782246 hasRelatedWork W187890988 @default.
• W2912782246 hasRelatedWork W2046429755 @default.
• W2912782246 hasRelatedWork W2048813874 @default.
• W2912782246 hasRelatedWork W2054748203 @default.
• W2912782246 hasRelatedWork W2064858900 @default.
• W2912782246 hasRelatedWork W2073564793 @default.
• W2912782246 hasRelatedWork W3084176453 @default.
• W2912782246 hasRelatedWork W4200006144 @default.
• W2912782246 hasRelatedWork W4256085234 @default.
• W2912782246 hasRelatedWork W4312083527 @default.
• W2912782246 hasVolume "13" @default.
• W2912782246 isParatext "false" @default.

• next